World's Best Scientists 2026 revealed!
Award Badge
Immunology
Thailand
2026

D-Index & Metrics

Immunology

D-Index
63
Citations
16663
World Ranking
2993
National Ranking
2

Research.com Recognitions

  • 2026 - Research.com Immunology in Thailand Leader Award
  • 2025 - Research.com Immunology in Thailand Leader Award

Overview

Kiat Ruxrungtham is affiliated with Chulalongkorn University in Thailand. Their research is primarily focused on medicine with significant contributions in immunology and microbiology. The scientist's main subfields of study include infectious diseases, virology, epidemiology, immunology, and emergency medicine.

Their work emphasizes several core topics such as HIV research and treatment, HIV/AIDS research and interventions, SARS-CoV-2 and COVID-19 research, HIV-related health complications and treatments, HIV/AIDS drug development and treatment, viral gastroenteritis research and epidemiology, as well as vaccine coverage and hesitancy.

Frequent publication venues for Kiat Ruxrungtham include:

  • Asian Pacific Journal of Allergy and Immunology
  • Vaccines
  • Journal of the International AIDS Society
  • PLoS ONE
  • Clinical Infectious Diseases

Some of the recent papers authored by the scientist are:

  • COVID-19 and HIV infection co-pandemics and their impact: a review of the literature, 2021, AIDS Research and Therapy
  • Plant-Produced Receptor-Binding Domain of SARS-CoV-2 Elicits Potent Neutralizing Responses in Mice and Non-human Primates, 2021, Frontiers in Plant Science
  • Sleep Quality of Hospitalized Patients, Contributing Factors, and Prevalence of Associated Disorders, 2020, Sleep Disorders
  • HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective, 2023, Antiviral Therapy
  • DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice, 2021, PLoS ONE

Kiat Ruxrungtham collaborates frequently with several researchers, including:

  • Stephen J. Kerr
  • Anchalee Avihingsanon
  • Chutitorn Ketloy
  • Sivaporn Gatechompol
  • Eakachai Prompetchara

Best Publications

  • Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection

    Netanya Sandler;Handan Wand;Annelys Roque;Matthew G Law

  • Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

    F van Leth;P Phanuphak;K Ruxrungtham;E Baraldi

  • Comprehensive serological profiling of human populations using a synthetic human virome

    George J. Xu;Tomasz Kula;Tomasz Kula;Qikai Xu;Qikai Xu;Mamie Z. Li;Mamie Z. Li

  • Life expectancy of HIV‐positive people after starting combination antiretroviral therapy: a meta‐analysis

    S Teeraananchai;SJ Kerr;SJ Kerr;J Amin;K Ruxrungtham

  • Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.

    Calvin J Cohen;Jaime Andrade-Villanueva;Bonaventura Clotet;Jan Fourie

  • Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

    José Valdez Madruga;Daniel Berger;Marilyn McMurchie;Fredy Suter

  • HIV/AIDS in Asia

    Kiat Ruxrungtham;Tim Brown;Praphan Phanuphak

  • Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.

    Anthony M. Mills;Mark Nelson;Dushyantha Jayaweera;Kiat Ruxrungtham

  • CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1 : results of the staccato randomised trial

    Jintanat Ananworanich;Angèle Gayet-Ageron;Michelle Le Braz;Wisit Prasithsirikul

  • Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

    John Gregson;Michele Tang;Nicaise Ndembi;Raph L Hamers

  • Cognitive Function and Neurodevelopmental Outcomes in HIV-Infected Children Older than 1 Year of Age Randomized to Early Versus Deferred Antiretroviral Therapy: The PREDICT Neurodevelopmental Study

    Thanyawee Puthanakit;Jintanat Ananworanich;Saphonn Vonthanak;Pope Kosalaraksa

  • Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort.

    W. Phillip Law;Chris J. Duncombe;Apicha Mahanontharit;Mark A. Boyd

  • Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent

    Jing Yuan;Sheng Guo;David Hall;Anna M Cammett

  • A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand

    Gail V. Matthews;Anchalee Avihingsanon;Sharon R. Lewin;Sharon R. Lewin;Janaki Amin

  • Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.

    W. Phillip Law;Gregory J. Dore;Chris J. Duncombe;Apicha Mahanontharit

  • A Randomized Trial Comparing Plasma Drug Concentrations and Efficacies between 2 Nonnucleoside Reverse-Transcriptase Inhibitor-Based Regimens in HIV-Infected Patients Receiving Rifampicin: The N2R Study

    Weerawat Manosuthi;Weerawat Manosuthi;Somnuek Sungkanuparph;Preecha Tantanathip;Aroon Lueangniyomkul

  • Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults.

    Sharon Walmsley;Sharon Walmsley;Anchalee Avihingsanon;Jihad Slim;Douglas J Ward

  • Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial.

    Anton L Pozniak;Javier Morales-Ramirez;Elly Katabira;Dewald Steyn

  • Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.

    Richard T Davey;Eduardo Fernández-Cruz;Norman Markowitz;Sarah Pett

  • Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.

    Pedro Cahn;Jan Fourie;Beatriz Grinsztejn;Sally Hodder

  • Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates.

    Chutitorn Ketloy;Anneke Engering;Utaiwan Srichairatanakul;Amporn Limsalakpetch

  • Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results.

    Weerawat Manosuthi;Sasisopin Kiertiburanakul;Somnuek Sungkanuparph;Kiat Ruxrungtham

  • Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial

    Ananworanich J;Nuesch R;Le Braz M;Chetchotisakd P

Frequent Co-Authors

Jintanat Ananworanich
Jintanat Ananworanich Moderna Therapeutics (United States)
David A. Cooper
David A. Cooper University of New South Wales
Sharon R. Lewin
Sharon R. Lewin University of Melbourne
David M. Burger
David M. Burger Radboud University
Joep M. A. Lange
Joep M. A. Lange University of Amsterdam
Gail V. Matthews
Gail V. Matthews University of New South Wales
Sean Emery
Sean Emery University of New South Wales
Gregory J. Dore
Gregory J. Dore University of New South Wales
Matthew Law
Matthew Law University of New South Wales
Stephen Locarnini
Stephen Locarnini Melbourne Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to various healthcare and research careers. For those interested in expanding their clinical skills, exploring accelerated NP programs can be an excellent way to advance quickly into nurse practitioner roles, combining immunology knowledge with hands-on patient care.

If you’re starting without a nursing background, consider online options like online ADN programs for non nurses. These programs provide foundational nursing education, paving the way toward careers that intersect with immunology in clinical settings.

For those aiming to become registered nurses efficiently, the easiest ABSN programs to get into offer practical pathways. These accelerated bachelor degrees balance rigorous coursework with flexibility, helping students step into immunology-adjacent roles faster.

Lastly, entry-level healthcare roles in immunology-related fields can start with programs like the easiest LPN programs to get into. Licensed Practical Nurse programs provide essential clinical training that supports roles in immunology labs or patient care settings.

Best Scientists Citing Kiat Ruxrungtham

Trending Scientists

Recently Published Articles